177 related articles for article (PubMed ID: 23104721)
1. A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.
Seiwert TY; Darga T; Haraf D; Blair EA; Stenson K; Cohen EE; Salama JK; Villaflor V; Witt ME; Lingen MW; Weichselbaum RR; Vokes EE
Ann Oncol; 2013 Mar; 24(3):769-76. PubMed ID: 23104721
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.
Seiwert TY; Haraf DJ; Cohen EE; Stenson K; Witt ME; Dekker A; Kocherginsky M; Weichselbaum RR; Chen HX; Vokes EE
J Clin Oncol; 2008 Apr; 26(10):1732-41. PubMed ID: 18375903
[TBL] [Abstract][Full Text] [Related]
3. EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II study.
Hecht JR; Farrell JJ; Senzer N; Nemunaitis J; Rosemurgy A; Chung T; Hanna N; Chang KJ; Javle M; Posner M; Waxman I; Reid A; Erickson R; Canto M; Chak A; Blatner G; Kovacevic M; Thornton M
Gastrointest Endosc; 2012 Feb; 75(2):332-8. PubMed ID: 22248601
[TBL] [Abstract][Full Text] [Related]
4. Prior chemoradiotherapy adversely impacts outcomes of recurrent and second primary head and neck cancer treated with concurrent chemotherapy and reirradiation.
Choe KS; Haraf DJ; Solanki A; Cohen EE; Seiwert TY; Stenson KM; Blair EA; Portugal L; Villaflor VM; Witt ME; Vokes EE; Salama JK
Cancer; 2011 Oct; 117(20):4671-8. PubMed ID: 21671479
[TBL] [Abstract][Full Text] [Related]
5. Phase I evaluation of TNFerade biologic plus chemoradiotherapy before esophagectomy for locally advanced resectable esophageal cancer.
Chang KJ; Reid T; Senzer N; Swisher S; Pinto H; Hanna N; Chak A; Soetikno R
Gastrointest Endosc; 2012 Jun; 75(6):1139-46.e2. PubMed ID: 22520270
[TBL] [Abstract][Full Text] [Related]
6. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck.
Varveris H; Mazonakis M; Vlachaki M; Kachris S; Lyraraki E; Zoras O; Maris T; Froudarakis M; Velegrakis J; Perysinakis C; Damilakis J; Samonis G
Oncol Rep; 2003; 10(1):185-95. PubMed ID: 12469168
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
Brockstein B; Haraf DJ; Stenson K; Fasanmade A; Stupp R; Glisson B; Lippman SM; Ratain MJ; Sulzen L; Klepsch A; Weichselbaum RR; Vokes EE
J Clin Oncol; 1998 Feb; 16(2):735-44. PubMed ID: 9469365
[TBL] [Abstract][Full Text] [Related]
8. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer.
Vokes EE; Haraf DJ; Mick R; McEvilly JM; Weichselbaum RR
J Clin Oncol; 1994 Nov; 12(11):2351-9. PubMed ID: 7525886
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of concomitant chemoradiotherapy with irinotecan, 5-FU, and hydroxyurea for patients with advanced and/or recurrent head and neck cancer.
Salama JK; Haraf DJ; Stenson K; Milano MT; Witt ME; Vokes EE
Cancer J; 2005; 11(2):140-6. PubMed ID: 15969989
[TBL] [Abstract][Full Text] [Related]
10. Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.
Spencer SA; Harris J; Wheeler RH; Machtay M; Schultz C; Spanos W; Rotman M; Meredith R; Ang KK
Head Neck; 2008 Mar; 30(3):281-8. PubMed ID: 17764087
[TBL] [Abstract][Full Text] [Related]
11. Induction chemotherapy followed by concurrent chemoradiation for advanced head and neck cancer: improved disease control and survival.
Kies MS; Haraf DJ; Athanasiadis I; Kozloff M; Mittal B; Pelzer H; Rademaker AW; Wenig B; Weichselbaum RR; Vokes EE
J Clin Oncol; 1998 Aug; 16(8):2715-21. PubMed ID: 9704722
[TBL] [Abstract][Full Text] [Related]
12. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).
Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K
Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 study of everolimus + weekly cisplatin + intensity modulated radiation therapy in head-and-neck cancer.
Fury MG; Lee NY; Sherman E; Ho AL; Rao S; Heguy A; Shen R; Korte S; Lisa D; Ganly I; Patel S; Wong RJ; Shaha A; Shah J; Haque S; Katabi N; Pfister DG
Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):479-86. PubMed ID: 24074921
[TBL] [Abstract][Full Text] [Related]
14. Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer.
Seiwert TY; Melotek JM; Blair EA; Stenson KM; Salama JK; Witt ME; Brisson RJ; Chawla A; Dekker A; Lingen MW; Kocherginsky M; Villaflor VM; Cohen EE; Haraf DJ; Vokes EE
Int J Radiat Oncol Biol Phys; 2016 Sep; 96(1):21-9. PubMed ID: 27511844
[TBL] [Abstract][Full Text] [Related]
15. A phase I trial of erlotinib and concurrent chemoradiotherapy for stage III and IV (M0) squamous cell carcinoma of the head and neck.
Gilbert J; Rudek MA; Higgins MJ; Zhao M; Bienvenu S; Tsottles N; Chaudhry MA; Wahl R; Forastiere A; Gillison M
Clin Cancer Res; 2012 Mar; 18(6):1735-42. PubMed ID: 22271880
[TBL] [Abstract][Full Text] [Related]
16. Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naïve locally advanced upper aerodigestive malignancy.
Langer CJ; Duffy K; Horwitz EM; Litwin S; Rosvold E; Schol J; Keenan E; Nicolaou N; Friedman CD; Ridge JA
Cancer Invest; 2006 Mar; 24(2):164-73. PubMed ID: 16537186
[TBL] [Abstract][Full Text] [Related]
17. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
Prestwich RJ; Öksüz DÇ; Dyker K; Coyle C; Şen M
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e237-43. PubMed ID: 21620580
[TBL] [Abstract][Full Text] [Related]
18. A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer.
Hitt R; Grau JJ; López-Pousa A; Berrocal A; García-Girón C; Irigoyen A; Sastre J; Martínez-Trufero J; Brandariz Castelo JA; Verger E; Cruz-Hernández JJ;
Ann Oncol; 2014 Jan; 25(1):216-25. PubMed ID: 24256848
[TBL] [Abstract][Full Text] [Related]
19. A Phase I/II trial of concurrent docetaxel and radiation after induction chemotherapy in patients with poor prognosis squamous cell carcinoma of the head and neck.
Tishler RB; Norris CM; Colevas AD; Lamb CC; Karp D; Busse PM; Nixon A; Frankenthaler R; Lake-Willcutt B; Costello R; Case M; Posner MR
Cancer; 2002 Oct; 95(7):1472-81. PubMed ID: 12237916
[TBL] [Abstract][Full Text] [Related]
20. Functional organ preservation after chemoradiotherapy in elderly patients with loco-regionally advanced head and neck squamous cell carcinoma.
Boscolo-Rizzo P; Muzzi E; Trabalzini F; Gava A; Stellin M; Da Mosto MC
Eur Arch Otorhinolaryngol; 2011 Sep; 268(9):1349-55. PubMed ID: 21258812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]